WO1997020938A3 - Zellen mit hybridrezeptor und dadurch steuerbarem genkonstrukt, und verwendung dieser zellen in der gentherapie - Google Patents

Zellen mit hybridrezeptor und dadurch steuerbarem genkonstrukt, und verwendung dieser zellen in der gentherapie Download PDF

Info

Publication number
WO1997020938A3
WO1997020938A3 PCT/DE1996/002334 DE9602334W WO9720938A3 WO 1997020938 A3 WO1997020938 A3 WO 1997020938A3 DE 9602334 W DE9602334 W DE 9602334W WO 9720938 A3 WO9720938 A3 WO 9720938A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
hybrid receptor
receptor
cell
gene
Prior art date
Application number
PCT/DE1996/002334
Other languages
English (en)
French (fr)
Other versions
WO1997020938A2 (de
Inventor
Roland Mertelsmann
Peter Kulmburg
Felicia Rosenthal
Original Assignee
Univ Ludwigs Albert
Roland Mertelsmann
Peter Kulmburg
Felicia Rosenthal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ludwigs Albert, Roland Mertelsmann, Peter Kulmburg, Felicia Rosenthal filed Critical Univ Ludwigs Albert
Priority to AU18686/97A priority Critical patent/AU1868697A/en
Publication of WO1997020938A2 publication Critical patent/WO1997020938A2/de
Publication of WO1997020938A3 publication Critical patent/WO1997020938A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung offenbart Zellen mit einem Hybridrezeptor, der einen an der Außenseite der Zelle lokalisierten, für ein bestimmtes Signalmolekül spezifischen Rezeptorteil und ein von einem anderen Rezeptor stammendes, im Inneren der Zelle lokalisiertes Rezeptorteil, das im Zellinneren ein Signal auslösen kann, umfaßt, wobei die Zelle wenigstens ein weiteres Genkonstrukt enthält, das einen Steuerbereich aufweist, der mit dem von dem Hybridrezeptor ausgesandten Signal interagieren kann und dadurch die Expression eines mit diesem Steuerbereich verbundenen Transgens steuern kann, sowie Verfahren zu deren Herstellung und die Verwendung der Zellen in der Gentherapie.
PCT/DE1996/002334 1995-12-05 1996-12-03 Zellen mit hybridrezeptor und dadurch steuerbarem genkonstrukt, und verwendung dieser zellen in der gentherapie WO1997020938A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU18686/97A AU1868697A (en) 1995-12-05 1996-12-03 Cells with hybrid receptor and gene construct which can be controlled by said hybrid receptor, and use of said cells in gene therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19545351.4 1995-12-05
DE1995145351 DE19545351C1 (de) 1995-12-05 1995-12-05 Eukaryotische Zellen mit Hybridrezeptor und dadurch steuerbarem Genkonstrukt, Verfahren zu deren Herstellung und Verwendung dieser Zellen in der Gentherapie

Publications (2)

Publication Number Publication Date
WO1997020938A2 WO1997020938A2 (de) 1997-06-12
WO1997020938A3 true WO1997020938A3 (de) 2002-02-14

Family

ID=7779244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1996/002334 WO1997020938A2 (de) 1995-12-05 1996-12-03 Zellen mit hybridrezeptor und dadurch steuerbarem genkonstrukt, und verwendung dieser zellen in der gentherapie

Country Status (3)

Country Link
AU (1) AU1868697A (de)
DE (1) DE19545351C1 (de)
WO (1) WO1997020938A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
IL136511A0 (en) 2000-06-01 2001-06-14 Gavish Galilee Bio Appl Ltd Genetically engineered mhc molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018317A1 (en) * 1993-02-12 1994-08-18 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
WO1995020670A1 (en) * 1994-01-28 1995-08-03 Targeted Genetics Corporation Cd 69 transcriptional regulatory elements

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018317A1 (en) * 1993-02-12 1994-08-18 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
WO1995020670A1 (en) * 1994-01-28 1995-08-03 Targeted Genetics Corporation Cd 69 transcriptional regulatory elements

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. MORITZ ET AL: "Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, May 1994 (1994-05-01), WASHINGTON US, pages 4318 - 4322, XP000647482 *
DATABASE MEDLINE, Accession no 95102497 *
S. ZIEGLER ET AL: "The activation antigen CD69", STEM CELLS, vol. 12, no. 5, September 1994 (1994-09-01), pages 456 - 465 *
T. BROCKER ET AL: "New simplified molecular design for functional T cell receptor", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, 1993, pages 1435 - 1439, XP000673214 *

Also Published As

Publication number Publication date
AU1868697A (en) 1997-06-27
WO1997020938A2 (de) 1997-06-12
DE19545351C1 (de) 1997-07-31

Similar Documents

Publication Publication Date Title
WO1998011243A3 (en) Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein
WO1998012311A3 (en) Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
HK1017903A1 (en) Process for controlling sialylation of proteins produced by mammalian cell culture.
EP0844888A4 (de) Gewebsspezifische virale vektoren
AU2001278797A1 (en) Expression vector using for animal cell
WO1998042851A8 (en) Plants with modified growth
WO2002029075A3 (en) Multiple inducible gene regulation system
CA2133203A1 (en) Hybrid human/porcine factor viii
SG108208A1 (en) Connective tissue growth factor
WO1996021007A3 (en) Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
MX9705039A (es) Genes y proteinas de muerte celular programada.
WO1998028317A3 (en) Synthesis of nucleosides and polynucleotides
AU716500B2 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
AU5539898A (en) Nucleic acid construct for the cell cycle regulated expression of structural genes
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU2162699A (en) Method for grafting lignin, polymerizates produced according to the method and the utilization thereof
AU2667995A (en) Chimerical peptide-nucleic acid fragment, process for producing the same and its use for appropriately introducing nucleic acids into cell organelles and cells
WO1997020938A3 (de) Zellen mit hybridrezeptor und dadurch steuerbarem genkonstrukt, und verwendung dieser zellen in der gentherapie
EP0068375A3 (de) Rekombinante DNS Technik zur Herstellung von Relaxin
AU1814995A (en) Galanin receptor, nucleic acids, transformed cells and uses thereof
EP0879888A3 (de) Patched-2 Polypeptide und Polynucleotide und Methoden zu ihrer Herstellung
WO2000073420A3 (en) Creation of human tumorigenic cells and uses therefor
CA2032035A1 (en) Fungal expression system
WO2001029178A3 (en) Epo primary response gene 1, eprg1
WO2001036463A3 (en) Genes specifically expressed in human dendritic cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97520871

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE